These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 7517553)

  • 21. Pyrido [1,2a] indole derivatives identified as novel non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
    Taylor DL; Ahmed PS; Chambers P; Tyms AS; Bedard J; Duchaine J; Falardeau G; Lavallée JF; Brown W; Rando RF; Bowlin T
    Antivir Chem Chemother; 1999 Mar; 10(2):79-86. PubMed ID: 10335402
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differences in the inhibition of human immunodeficiency virus type 1 reverse transcriptase DNA polymerase activity by analogs of nevirapine and [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1", 2"-oxathiole-2",2"-dioxide] (TSAO).
    Arion D; Fletcher RS; Borkow G; Camarasa MJ; Balzarini J; Dmitrienko GI; Parniak MA
    Mol Pharmacol; 1996 Nov; 50(5):1057-64. PubMed ID: 8913335
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Common features in the interaction of tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione and 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives with the human immunodeficiency virus type 1 reverse transcriptase.
    Debyser Z; Pauwels R; Baba M; Desmyter J; De Clercq E
    Mol Pharmacol; 1992 May; 41(5):963-8. PubMed ID: 1375320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV.
    Witvrouw M; Pannecouque C; Van Laethem K; Desmyter J; De Clercq E; Vandamme AM
    AIDS; 1999 Aug; 13(12):1477-83. PubMed ID: 10465070
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sensitivity of (138 Glu-->Lys) mutated human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) to HIV-1-specific RT inhibitors.
    Balzarini J; Kleim JP; Riess G; Camarasa MJ; De Clercq E; Karlsson A
    Biochem Biophys Res Commun; 1994 Jun; 201(3):1305-12. PubMed ID: 7517668
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture.
    Richman D; Shih CK; Lowy I; Rose J; Prodanovich P; Goff S; Griffin J
    Proc Natl Acad Sci U S A; 1991 Dec; 88(24):11241-5. PubMed ID: 1722324
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication.
    Balzarini J; Pelemans H; Aquaro S; Perno CF; Witvrouw M; Schols D; De Clercq E; Karlsson A
    Mol Pharmacol; 1996 Aug; 50(2):394-401. PubMed ID: 8700148
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resistance to 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives is generated by mutations at multiple sites in the HIV-1 reverse transcriptase.
    Buckheit RW; Fliakas-Boltz V; Yeagy-Bargo S; Weislow O; Mayers DL; Boyer PL; Hughes SH; Pan BC; Chu SH; Bader JP
    Virology; 1995 Jun; 210(1):186-93. PubMed ID: 7540784
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''- oxathiole-2'',2'-dioxide)pyrimidine (TSAO) nucleoside analogues: highlyselective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase.
    Balzarini J; Pérez-Pérez MJ; San-Félix A; Schols D; Perno CF; Vandamme AM; Camarasa MJ; De Clercq E
    Proc Natl Acad Sci U S A; 1992 May; 89(10):4392-6. PubMed ID: 1374900
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant.
    Das K; Ding J; Hsiou Y; Clark AD; Moereels H; Koymans L; Andries K; Pauwels R; Janssen PA; Boyer PL; Clark P; Smith RH; Kroeger Smith MB; Michejda CJ; Hughes SH; Arnold E
    J Mol Biol; 1996 Dec; 264(5):1085-100. PubMed ID: 9000632
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV-1-specific RT inhibitors: highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase.
    De Clercq E
    Med Res Rev; 1993 May; 13(3):229-58. PubMed ID: 7683360
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74-->Val or Ile and Val-75-->Leu or Ile) HIV-1 mutants.
    Kleim JP; Rösner M; Winkler I; Paessens A; Kirsch R; Hsiou Y; Arnold E; Riess G
    Proc Natl Acad Sci U S A; 1996 Jan; 93(1):34-8. PubMed ID: 8552634
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New tetrahydroimidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2',3'-dideoxynucleoside analogs.
    Pauwels R; Andries K; Debyser Z; Kukla MJ; Schols D; Breslin HJ; Woestenborghs R; Desmyter J; Janssen MA; De Clercq E
    Antimicrob Agents Chemother; 1994 Dec; 38(12):2863-70. PubMed ID: 7535037
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Functional analysis of HIV-1 reverse transcriptase amino acids involved in resistance to multiple nonnucleoside inhibitors.
    Sardana VV; Emini EA; Gotlib L; Graham DJ; Lineberger DW; Long WJ; Schlabach AJ; Wolfgang JA; Condra JH
    J Biol Chem; 1992 Sep; 267(25):17526-30. PubMed ID: 1381350
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential inhibitory effects of TIBO derivatives on different strains of simian immunodeficiency virus.
    Debyser Z; De Vreese K; Pauwels R; Yamamoto N; Anné J; De Clercq E; Desmyter J
    J Gen Virol; 1992 Jul; 73 ( Pt 7)():1799-804. PubMed ID: 1378481
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human immunodeficiency virus type 1 reverse transcriptase dimer destabilization by 1-[Spiro[4"-amino-2",2" -dioxo-1",2" -oxathiole-5",3'-[2', 5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]]]-3-ethylthy mine.
    Sluis-Cremer N; Dmitrienko GI; Balzarini J; Camarasa MJ; Parniak MA
    Biochemistry; 2000 Feb; 39(6):1427-33. PubMed ID: 10684624
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enzymatic properties of two mutants of reverse transcriptase of human immunodeficiency virus type 1 (tyrosine 181-->isoleucine and tyrosine 188-->leucine), resistant to nonnucleoside inhibitors.
    Loya S; Bakhanashvili M; Tal R; Hughes SH; Boyer PL; Hizi A
    AIDS Res Hum Retroviruses; 1994 Aug; 10(8):939-46. PubMed ID: 7529032
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase.
    Mellors JW; Dutschman GE; Im GJ; Tramontano E; Winkler SR; Cheng YC
    Mol Pharmacol; 1992 Mar; 41(3):446-51. PubMed ID: 1372083
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of human immunodeficiency virus type 1 wild-type and mutant reverse transcriptases by the phenyl ethyl thiazolyl thiourea derivatives trovirdine and MSC-127.
    Zhang H; Vrang L; Bäckbro K; Lind P; Sahlberg C; Unge T; Oberg B
    Antiviral Res; 1995 Dec; 28(4):331-42. PubMed ID: 8669892
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A drug resistance mutation in the inhibitor binding pocket of human immunodeficiency virus type 1 reverse transcriptase impairs DNA synthesis and RNA degradation.
    Fan N; Rank KB; Slade DE; Poppe SM; Evans DB; Kopta LA; Olmsted RA; Thomas RC; Tarpley WG; Sharma SK
    Biochemistry; 1996 Jul; 35(30):9737-45. PubMed ID: 8703945
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.